NO20061797L - Trombinreseptorantagonister - Google Patents

Trombinreseptorantagonister

Info

Publication number
NO20061797L
NO20061797L NO20061797A NO20061797A NO20061797L NO 20061797 L NO20061797 L NO 20061797L NO 20061797 A NO20061797 A NO 20061797A NO 20061797 A NO20061797 A NO 20061797A NO 20061797 L NO20061797 L NO 20061797L
Authority
NO
Norway
Prior art keywords
thrombin
polymorphs
solvates
binders
salts
Prior art date
Application number
NO20061797A
Other languages
English (en)
Norwegian (no)
Inventor
Samuel Chackalamannil
Mariappan Chelliah
Yan Xia
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20061797L publication Critical patent/NO20061797L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
NO20061797A 2003-09-25 2006-04-24 Trombinreseptorantagonister NO20061797L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/671,216 US7488742B2 (en) 2000-06-15 2003-09-25 Thrombin receptor antagonists
PCT/US2004/031495 WO2005030712A2 (en) 2003-09-25 2004-09-23 Thrombin receptor antagonists

Publications (1)

Publication Number Publication Date
NO20061797L true NO20061797L (no) 2006-05-19

Family

ID=34393462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061797A NO20061797L (no) 2003-09-25 2006-04-24 Trombinreseptorantagonister

Country Status (21)

Country Link
US (3) US7488742B2 (pt)
EP (1) EP1663965B1 (pt)
JP (1) JP4694490B2 (pt)
KR (1) KR20060128848A (pt)
CN (1) CN101128457A (pt)
AR (1) AR045809A1 (pt)
AU (1) AU2004276327B2 (pt)
BR (1) BRPI0414592A (pt)
CA (1) CA2540163C (pt)
CO (1) CO5680428A2 (pt)
EC (1) ECSP066455A (pt)
IL (1) IL174538A0 (pt)
MX (1) MXPA06003379A (pt)
MY (1) MY143834A (pt)
NO (1) NO20061797L (pt)
PE (1) PE20050471A1 (pt)
RU (1) RU2367660C9 (pt)
SG (1) SG147466A1 (pt)
TW (1) TWI331608B (pt)
WO (1) WO2005030712A2 (pt)
ZA (1) ZA200602448B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
ATE494284T1 (de) * 2002-04-16 2011-01-15 Schering Corp Tricyclischer thrombinrezeptorantagonist
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
DE602005009355D1 (de) * 2004-05-28 2008-10-09 Schering Corp Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
EP1778652A2 (en) * 2004-08-20 2007-05-02 EntreMed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
CA2582639A1 (en) 2004-10-08 2006-04-20 Schering Corporation Thrombin receptor antagonists
EP1829874B1 (en) * 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
DK1848705T3 (da) 2005-01-14 2010-06-14 Schering Corp EXO- og diastereoselektive synteser af himbacin-analoger
CA2601575A1 (en) * 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
CN101384590A (zh) * 2005-12-22 2009-03-11 先灵公司 作为凝血酶受体拮抗剂的唑并异喹啉
JP2009521472A (ja) * 2005-12-22 2009-06-04 シェーリング コーポレイション 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト
CN101460463A (zh) * 2006-03-29 2009-06-17 先灵公司 可作为凝血酶受体拮抗剂的单环和双环喜巴辛衍生物
PE20080183A1 (es) * 2006-04-06 2008-03-10 Schering Corp Terapias de combinacion de tra
EP2266976B1 (en) * 2006-04-13 2013-07-31 Merck Sharp & Dohme Corp. Fused ring thrombin receptor antagonists
KR20090031544A (ko) 2006-06-29 2009-03-26 쉐링 코포레이션 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) * 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
JP2010505842A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体
CA2673228A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
JP2010522169A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション トロンビン受容体アンタゴニストの使用による、経皮的インターベンション後の有害事象の低減
MX2010008490A (es) * 2008-02-05 2010-08-18 Sanofi Aventis Triazolopiridazinas como inhibidores de par1, su produccion y su uso como medicamentos.
KR20100120139A (ko) 2008-02-05 2010-11-12 사노피-아벤티스 Par1 억제제로서의 트리아졸륨 염, 이들의 제조방법, 및 약제로서의 용도
ES2400322T3 (es) 2008-02-05 2013-04-09 Sanofi Derivados de SF5 como inhibidores de PAR-1, su preparación y utilización como medicamento
JP5789256B2 (ja) 2009-06-04 2015-10-07 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. トロンビン受容体アンタゴニストの活性代謝物
AU2010259003A1 (en) 2009-06-08 2011-11-10 Merck Sharp & Dohme Corp. A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2011128421A1 (de) 2010-04-16 2011-10-20 Sanofi Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren
PL2558462T3 (pl) 2010-04-16 2015-03-31 Sanofi Sa Pirydylo-winylo-pirazolo-chinoliny jako inhibitory PAR1
EP2822557B1 (en) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
EP3035930A4 (en) 2013-08-22 2017-03-08 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
EP3035929A4 (en) 2013-08-22 2017-03-15 Merck Sharp & Dohme Corp. 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
US9808473B2 (en) 2013-08-22 2017-11-07 Merck Sharp & Dohme Corp. Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
WO2016114386A1 (ja) * 2015-01-15 2016-07-21 国立研究開発法人国立精神・神経医療研究センター 進行型免疫性脱髄疾患治療剤
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000229961A (ja) * 1998-12-11 2000-08-22 Sagami Chem Res Center ヒドロナフト[2,3−c]フラン誘導体およびその製造方法
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
KR100604742B1 (ko) * 2000-06-15 2006-07-26 쉐링 코포레이션 트롬빈 수용체 길항제
EP1436298B1 (en) * 2001-10-18 2011-09-21 Schering Corporation Himbacine analogues as thrombin receptor antagonists
ATE494284T1 (de) * 2002-04-16 2011-01-15 Schering Corp Tricyclischer thrombinrezeptorantagonist
DE602005009355D1 (de) * 2004-05-28 2008-10-09 Schering Corp Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
CN101137636A (zh) * 2005-01-14 2008-03-05 先灵公司 Himbacine类似物的外型选择性合成
DK1848705T3 (da) * 2005-01-14 2010-06-14 Schering Corp EXO- og diastereoselektive synteser af himbacin-analoger
AR056262A1 (es) * 2005-01-14 2007-10-03 Schering Corp Preparacion de alcoholes propargilicos y esteres intermediarios de analogos de himbacina

Also Published As

Publication number Publication date
AU2004276327B2 (en) 2010-10-07
US20040152736A1 (en) 2004-08-05
TW200524914A (en) 2005-08-01
AU2004276327A1 (en) 2005-04-07
WO2005030712A2 (en) 2005-04-07
CN101128457A (zh) 2008-02-20
BRPI0414592A (pt) 2006-11-07
SG147466A1 (en) 2008-11-28
US20090069383A1 (en) 2009-03-12
PE20050471A1 (es) 2005-08-24
WO2005030712A8 (en) 2007-12-21
IL174538A0 (en) 2006-08-01
CO5680428A2 (es) 2006-09-29
TWI331608B (en) 2010-10-11
AR045809A1 (es) 2005-11-16
JP4694490B2 (ja) 2011-06-08
JP2007523051A (ja) 2007-08-16
CA2540163C (en) 2012-06-05
MXPA06003379A (es) 2006-06-08
ZA200602448B (en) 2007-09-26
EP1663965A2 (en) 2006-06-07
RU2006113638A (ru) 2007-11-10
EP1663965B1 (en) 2014-04-09
MY143834A (en) 2011-07-15
US7488742B2 (en) 2009-02-10
KR20060128848A (ko) 2006-12-14
RU2367660C2 (ru) 2009-09-20
ECSP066455A (es) 2006-09-18
WO2005030712A3 (en) 2007-09-20
CA2540163A1 (en) 2005-04-07
US20090076088A1 (en) 2009-03-19
RU2367660C9 (ru) 2010-08-10

Similar Documents

Publication Publication Date Title
NO20061797L (no) Trombinreseptorantagonister
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
DE60335869D1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20071108L (no) Nye 4-benzylidenpiperidinderivater
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
NO20082330L (no) Nye krystallinske polymorfe former av lerkanidipinhydroklorid og fremgangsmate for fremstilling derav
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
NO20045120L (no) Triazolderivater som takykininreseptorantagonister
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
NO20080243L (no) Substituerte arylpyrazoler til anvendelse mot parasitter
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
ECSP066773A (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
TW200800943A (en) Indane derivatives as MCH receptor antagonists
SE0400284D0 (sv) Novel compounds
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
NO20071159L (no) Prodmedikamentsubstituerte benzoksazoler som ostrogene midler
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
EA200702612A1 (ru) Соединения бензимидазолкарбоксамида в качестве агонистов рецепторов 5-нт
CY1109694T1 (el) Παραγωγα πυρρολιδινης ως ανταγωνιστες υποδοχεα η3 ισταμινης
DK1893589T3 (da) Substituerede N-benzo[d]isoxazol-3-yl-amin-derivater som inhibitorer af mGluR5-, serotonin-(5-HT) og noradrenalinreceptorer og deres anvendelse til fremstilling af lægemidler
EA200700246A1 (ru) Трициклические производные пиразола в качестве модуляторов каннабиноидного рецептора
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application